Novel and Repurposed Antiviral Agents, 2nd Edition
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 576
Special Issue Editors
Interests: viral pathogenesis; antiviral agents; viral diagnosis
Special Issues, Collections and Topics in MDPI journals
Interests: viral pathogenesis and immunology; enterovirus; antiviral agents
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is a continuation of our previous Special Issue “Novel and Repurposed Antiviral Agents”.
The global outbreak of COVID-19 represents a significant threat for humanity. It is therefore an urgent and unmet need to search for antiviral therapeutics to fight against SARS-CoV-2. Re-positioning existing antiviral agents and screening their broad-spectrum antiviral activity against SARS-CoV-2 is pivotal. In addition to COVID-19, many epidemic viral diseases, such as influenza, dengue, Zika, Ebola, and Western/Eastern equine encephalitis, do not yet have effective therapies. Therefore, there are very few currently available drugs to control such virulent virus infections.
Developing novel and repurposed antiviral agents is a priority for treating epidemic diseases of emerging and re-emerging viruses. Targeting viral infectivity and modulating host defense systems are recognized as the main approaches to develop direct-acting antivirals (DAAs) and host-targeting agents (HTAs). The antiviral mechanisms of antiviral candidates should be extensively analyzed among different types of viral diseases. This Special Issue will serve as a platform for the study of DAAs and HTAs, facilitating the re-positioning of existing agents, herbal components, synthesized compounds, and genetic engineering molecules. We aim to explore the abilities of repurposed antiviral agents in the hope that they may become more promising for controlling future viral epidemics.
Prof. Dr. Cheng-Wen Lin
Dr. Szu-Hao Kung
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antiviral agent
- repurposed drug
- emerging virus
- direct-acting antiviral
- host-targeting agent
- molecular mechanism
